BioSpace News Archive

Drug Development

D&D Pharmatech Announces First Patient Dosed in Phase 1 Clinical Trial of DD01 in Obese Patients with Diabetes and NAFLD

DD01 is a long-acting dual agonist of GLP-1 and glucagon receptors, which resulted in weight loss, improved metabolic control and reduced fatty liver in animal models of human disease.

March 30, 2021
·
3 min read
Business

AavantiBio Appoints Dr. Christopher Wright as Chief Medical Officer

AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Christopher Wright, M.D., Ph.D., as Chief Medical Officer.

March 30, 2021
·
4 min read
Drug Development

Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study

Blinded data from the 600 mg dose cohort support the doses (400 mg v 200 mg v placebo) being evaluated in the Hibiscus Study currently enrolling people living with sickle cell disease (SCD) Doubling the dose of FT-4202 to 600 mg daily for 14 days compared to the previous 300 mg cohort was well-tolerated with no dose-limiting toxicities or treatment-related adverse events observed

March 30, 2021
·
8 min read
INBRAIN Neuroelectronics Secures $17 Million in Series A Funding for First AI-Powered Graphene-Brain Interface

Funding enables company to advance first-in-human studies for its flagship product, a less-invasive neuromodulation device for treating neurological conditions using artificial intelligence and graphene electrodes

March 30, 2021
·
6 min read